Below is an important message from one of our highly valued sponsors. Please read it carefully as they have some special information to share with you.
Dear Reader,
In this short 3-min. video, legendary investor James Altucher reveals the name and ticker symbol of a company he believes will skyrocket as soon as March 26th…
100% FREE of charge.
No tricks.
No gimmicks.
Free.
The company he reveals here is directly tied to the hotly anticipated IPO of Elon Musk’s Starlink…
Which is estimated to be worth $100 BILLION when it finally goes public.
That would make it the biggest IPO in history!
And right now – today…
You can get a “pre-IPO” recommendation on Starlink before it goes public…
From one of the most successful investors in the world – completely FREE of charge.
Click here to watch the video now.
It’s only 3 minutes long…
And it could give you an early stake in one of the biggest profit opportunities of all time.
Click here to check it out before it’s too late.
Best,
Matt Insley
Publisher, Paradigm Press
P.S. Starlink could go public as soon as March 26th. So for your chance at the biggest possible gains…
Make sure you act on this ASAP.
Click here to watch James’ urgent 3 min. video now.
DICK'S Sporting Goods Could Be Ready for Another Breakout
Authored by Thomas Hughes. Article Published: 3/14/2026.
Key Points
- DICK'S Sporting Goods posted fiscal Q4 revenue of over $6.2 billion, topping estimates by nearly 300 basis points as the Foot Locker integration begins to show results.
- Guidance came in below the earnings consensus, but management's revenue target beat at the low end, and the company expects an inflection starting with the back-to-school season.
- A $5 billion buyback authorization, a dividend increase, and institutional ownership near 90% underscore the capital return story building alongside the integration.
- Special Report: Elon Musk's $1 Quadrillion AI IPO
DICK'S Sporting Goods (NYSE: DKS) could reach a new all-time high this year. Its latest earnings report topped expectations, the growth outlook is improving, capital returns are flowing, and the Foot Locker integration is progressing.
Near-term headwinds persist, as reflected in guidance, but the cost of integration is temporary while revenue growth and improving core profitability should endure.
Stopping the Deadliest Animal on Earth (Ad)
Med-X is gearing up for a possible Nasdaq listing (ticker: MXRX). But the real opportunity is now – before they hit the big stage.
Their all-natural pesticides have outperformed chemical brands in independent lab tests, providing safer solutions without sacrificing results.
With $6.4M in sales in just four years, they're getting ready for the next step.
A key takeaway is an expected inflection later this year. The combination of integration efforts, store-count increases, and inventory rationalization positions the company for accelerated growth and profit improvement beginning in the second half of the year.
DICK'S Sporting Goods Has Hurdles But Can Easily Clear Them
Guidance may be viewed as a near-term hurdle, but early price action suggests the market will clear it. The company expects $14 at the midpoint of its adjusted EPS range, below the MarketBeat consensus of $14.83. The shortfall reflects integration costs and conservative guidance. Revenue guidance did come in above consensus at the low end, which implies future profitability could exceed both company guidance and analyst forecasts.
Valuation also looks attractive. Trading under 10x the projected 2030 outlook, the stock appears deeply undervalued. If the company exceeds that forecast, shares could plausibly rise 50%–100% over the next few years, with the higher end of that range a realistic possibility.
DICK'S Sporting Goods: Growth Fuels Robust Capital Return
Even if guidance appears tepid, it can be constructive for the stock. Revenue is expected to accelerate relative to consensus, and adjusted EPS is forecast to grow just under 10%, which should allow balance-sheet improvement, business reinvestment, and meaningful capital returns. Those capital returns—dividends and buybacks—underpin the long-term stock outlook.
The Foot Locker acquisition temporarily increased share count, but the fiscal-year report shows accelerated repurchases that should reduce the float in upcoming quarters. Buybacks aren't guaranteed, but management reinforced its commitment in early 2025 with a new three-year, $5 billion authorization.
Another sign of confidence is the dividend, which was increased just over 3% for 2026. At early March 2026 price levels it yields more than 2.5%, and management targets a payout ratio around 36% of EPS. That supports sustainable dividend growth and could help the company reach Dividend Aristocrat status over time.
DICK'S Knocks It Out of the Park With Fiscal Q4 Results
DICK'S Q4 results show strong momentum, helped by the Foot Locker acquisition, comp-store strength, and an improving store base. The company reported more than $6.2 billion in consolidated revenue, up 60.2% year over year and roughly 300 basis points above expectations.
On a segment basis, DICK'S grew over 3% on a same-store basis and saw margin improvement. Foot Locker's inclusion weighed on quarterly profitability, but adjusted EPS of $3.45 materially beat expectations—outperforming the consensus by a wide margin—and the company expects an inflection ahead.
Analysts didn't immediately issue broad revisions after the release, but commentary was generally positive. Recent upgrades and higher price targets lifted sentiment to Moderate Buy from Hold and pushed the MarketBeat consensus price target to about $240 (roughly 22% upside); higher-end targets add another ~20%. Institutional investors own nearly 90% of the stock and have been net buyers over the trailing 12 months, extending the bullish trend into early Q1 2026.
DICK'S Sporting Goods in Rebound Mode: Higher Prices to Follow
Shares responded favorably to the news, rising more than 5% in premarket trading and finding support at a key exponential moving average, which generated a trend-following buy signal. Similar signals have led to multi-month to multi-quarter rallies—sometimes lasting up to two years. The most likely path is continued upside into the back-to-school season, a test of the all-time high, and a potential breakout to new highs in the fall.
3 Companies at the Forefront of the GLP-1 Pill Wars
Submitted by Nathan Reiff. Publication Date: 3/16/2026.
Key Points
- Three companies to watch in the fast-growing GLP-1 space include firms with market capitalizations ranging from about $4 billion to nearly $1 trillion.
- Eli Lilly's size and dominant position allow it to develop multiple GLP-1 medicines and to expand rapidly into many corners of the world.
- Viking Therapeutics and Structure Therapeutics are much smaller, but each has a highly promising GLP-1 candidate working its way through the clinical trial process.
- Special Report: Elon Musk's $1 Quadrillion AI IPO
Though the first GLP-1 agonists date back more than 20 years, it's only in the last couple of years that they began to dominate the pharmaceutical space for their massive potential as weight-loss drugs. With some estimates placing the market at nearly $63 billion in early 2026, forecasts call for the GLP-1 industry to roughly triple over the coming decade.
It's no surprise the biopharma industry is racing to capture a share of that growth as GLP-1 use accelerates. Dozens of new GLP-1 receptor agonists are in development across nearly as many firms—and it's not just major pharma names that are getting involved. The class is evolving quickly and has expanded to include oral treatments, with a first-ever FDA approval for a GLP-1 pill for weight loss (Wegovy) at the end of 2025. Amid the turbulence and hype surrounding this fast-growing space, the companies below may be particularly interesting to watch.
Multiple Products and Geographies Could Cement Eli Lilly's Dominance
Stopping the Deadliest Animal on Earth (Ad)
Med-X is gearing up for a possible Nasdaq listing (ticker: MXRX). But the real opportunity is now – before they hit the big stage.
Their all-natural pesticides have outperformed chemical brands in independent lab tests, providing safer solutions without sacrificing results.
With $6.4M in sales in just four years, they're getting ready for the next step.
Eli Lilly and Company (NYSE: LLY) is one of the largest pharmaceutical companies in the world, with a market capitalization approaching $1 trillion as shares have climbed roughly 20% in the last year.
That scale gives Eli Lilly an advantage as it expands its GLP-1 program globally. The firm plans to spend $3 billion in China over the coming decade to expand its supply chain and build local manufacturing capacity, including for GLP-1 medications. That investment should both boost Lilly's access to China's growing weight-loss market and strengthen global supply.
In China, Lilly recently filed for approval of a new GLP-1 treatment and completed a Phase 1 trial for a related candidate. Last quarter, the company submitted orforglipron, a new GLP-1 agonist, for obesity treatment in the United States and more than three dozen additional countries, with an expected domestic launch by mid-2026. Lilly's large R&D budget has also enabled work on retatrutide, a so-called "triple-agonist" that combines GLP-1 activity with other mechanisms and is currently in trials.
By pursuing multiple products—including potential pill formulations—and expanding geographically, Lilly is positioning itself to be a dominant player in the GLP-1 market. With 45% year-over-year revenue growth in 2025, these efforts could help sustain rapid top-line gains going forward.
Viking's Dual Agonist Drug Shows Potential as It Advances Through Trials
A much smaller firm than Lilly, Viking Therapeutics Inc. (NASDAQ: VKTX) has not yet brought a GLP-1 drug to market. Its lead candidate, VK2735, is a dual agonist of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors and has been progressing through clinical trials. In January 2025, Viking published Phase 2 results for VK2735 showing strong potential, including up to nearly 15% of baseline body weight lost in participants and no clear plateau in effect.
Viking is developing VK2735 in both oral and injectable forms and expects to begin Phase 3 trials for the oral version in the coming months. So far the drug's promise has helped VKTX shares rise by nearly 20% in the past year.
That said, investors may worry about the company's ability to commercialize the drug quickly enough to capture significant market share, given the number of alternatives already available or close to approval. Viking is not yet profitable, although as of the latest quarter it held a healthy $706 million in cash reserves.
Structure's GLP-1 Pill Could Be Large, but Trial Results Will Decide
Shares of Structure Therapeutics (NASDAQ: GPCR) have far outperformed the companies above in the last year, rising more than 150% as investors grew enthusiastic about aleniglipron, the firm's GLP-1 agonist candidate.
Analysts remain bullish: consensus estimates imply upside potential of over 90% based on a price target of $107.90.
Compelling Phase 2B results published in December 2025 attracted headlines, and investors are now waiting for additional data. If aleniglipron proves to be a strong contender in the emerging GLP-1 pill market, GPCR shareholders could see further gains when new results arrive—but that outcome is not guaranteed and carries significant risk.
to bring you the latest market-moving news.
This message is a sponsored email from Paradigm Press, a third-party advertiser of TickerReport and MarketBeat.
Contact Us | Unsubscribe
© 2006-2026 MarketBeat Media, LLC dba TickerReport.
345 N Reid Pl. #620, Sioux Falls, S.D. 57103-7078. USA..
0 Response to "Altucher: My #1 FREE Stock Pick is NYSE: (___)"
Post a Comment